Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Time Perspective: Retrospective and Prospective
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CP-CML patients who have failed Imatinib 400 mg daily |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily | At 3 months post treatment change | |
| Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily | At 6 months post treatment change | |
| Complete Cytogenic Response (CCyR) for CP-CML patients who failed Imatinib 400 mg daily | At 12 months post treatment change |
| Measure | Description | Time Frame |
|---|---|---|
| Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily | Baseline | |
| Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily |
Not provided
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Not provided
Not provided
Not provided
Primary care clinic, academic and community oncology centers
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| BMS Clinical Trials Disclosure | View source |
| For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D015464 | Leukemia, Myelogenous, Chronic, BCR-ABL Positive |
| ID | Term |
|---|---|
| D007951 | Leukemia, Myeloid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| 3 months after start of treatment |
| Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily | 6 months after start of treatment |
| Prognostic factors (clinical and demographic characteristics) that influence treatment selection for CP-CML patients who fail imatinib 400 mg daily | 12 months after start of treatment |
| Best response rates achieved by patients if no CCyR | Baseline |
| Best response rates achieved by patients if no CCyR | 3 months after start of treatment |
| Best response rates achieved by patients if no CCyR | 6 months after start of treatment |
| Best response rates achieved by patients if no CCyR | 12 months after start of treatment |
| D009196 |
| Myeloproliferative Disorders |
| D001855 | Bone Marrow Diseases |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |